Literature DB >> 21664392

Advances in assay of complement function and activation.

Morten Harboe1, Ebbe Billmann Thorgersen, Tom Eirik Mollnes.   

Abstract

The main function of the complement system is pattern recognition of danger. Typical exogenous danger signals are pathogen associated molecular patterns inducing a protective inflammatory response. Other examples are exposure to foreign surfaces of biomedical materials including nanoparticles, which principally induce the same inflammatory response. If a surface is "foreign" to the host, it induces complement activation. Development of monoclonal antibodies to neoepitopes on complement activation products introduced an entirely new set of methods for assay of complement activation. Activation of complement by a surface occurs by impairment of the fine balance of the control system, e.g. by preferred binding of factor B at the expense of factor H. Sensitive methods to detect complement activation on surfaces and in the fluid phase are a prerequisite for investigation of the biocompatibility of artificial materials. This information can be used to develop new materials with enhanced biocompatibility. Here we review available methods to study human and animal complement function and activation in vitro and in vivo.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21664392     DOI: 10.1016/j.addr.2011.05.010

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  20 in total

1.  Complement and contact system activation in acute congestive heart failure patients.

Authors:  C Suffritti; E Tobaldini; R Schiavon; S Strada; L Maggioni; S Mehta; G Sandrone; E Toschi-Dias; M Cicardi; N Montano
Journal:  Clin Exp Immunol       Date:  2017-08-04       Impact factor: 4.330

2.  Assessment of Complement Activation by Nanoparticles: Development of a SPR Based Method and Comparison with Current High Throughput Methods.

Authors:  Jean-Baptiste Coty; Magali Noiray; Christine Vauthier
Journal:  Pharm Res       Date:  2018-04-26       Impact factor: 4.200

3.  Formation of Protein Corona on Nanoparticle Affects Different Complement Activation Pathways Mediated by C1q.

Authors:  Tingting Ding; Jiao Sun
Journal:  Pharm Res       Date:  2019-12-23       Impact factor: 4.200

4.  Complement Component C5 and TLR Molecule CD14 Mediate Heme-Induced Thromboinflammation in Human Blood.

Authors:  Anub M Thomas; Alexandra Gerogianni; Martin B McAdam; Yngvar Fløisand; Corinna Lau; Terje Espevik; Per H Nilsson; Tom Eirik Mollnes; Andreas Barratt-Due
Journal:  J Immunol       Date:  2019-08-14       Impact factor: 5.422

5.  Soluble membrane attack complex is diagnostic for intraventricular shunt infection in children.

Authors:  Theresa N Ramos; Anastasia A Arynchyna; Tessa E Blackburn; Scott R Barnum; James M Johnston
Journal:  JCI Insight       Date:  2016-07-07

6.  (5R)-5-hydroxytriptolide ameliorates anti-glomerular basement membrane glomerulonephritis in NZW mice by regulating Fcγ receptor signaling.

Authors:  Qing Qi; Heng Li; Ze-Min Lin; Xiao-Qian Yang; Feng-Hua Zhu; Yu-Ting Liu; Mei-Juan Shao; Lu-Yao Zhang; Yan-Sheng Xu; Yu-Xi Yan; Lan-Lan Sun; Shi-Jun He; Wei Tang; Jian-Ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2017-09-07       Impact factor: 6.150

7.  The role of properdin in zymosan- and Escherichia coli-induced complement activation.

Authors:  Morten Harboe; Peter Garred; Julie K Lindstad; Anne Pharo; Fredrik Müller; Gregory L Stahl; John D Lambris; Tom E Mollnes
Journal:  J Immunol       Date:  2012-07-30       Impact factor: 5.422

8.  Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission.

Authors:  E B Volokhina; D Westra; T J A M van der Velden; N C A J van de Kar; T E Mollnes; L P van den Heuvel
Journal:  Clin Exp Immunol       Date:  2015-08       Impact factor: 4.330

9.  Pulmonary Procoagulant and Innate Immune Responses in Critically Ill COVID-19 Patients.

Authors:  Esther J Nossent; Alex R Schuurman; Tom D Y Reijnders; Anno Saris; Ilse Jongerius; Siebe G Blok; Heder de Vries; JanWillem Duitman; Anton Vonk Noordegraaf; Lilian J Meijboom; René Lutter; Leo Heunks; Harm Jan Bogaard; Tom van der Poll
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

10.  Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.

Authors:  Peter Garred; Andrea J Tenner; Tom E Mollnes
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.